Zeria Pharmaceutical Co Ltd


Zeria Pharmaceutical Co Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,082.00
  • Today's Change-122.00 / -5.54%
  • Shares traded429.00k
  • 1 Year change+7.76%
  • Beta0.4199
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.

  • Revenue in JPY (TTM)66.16bn
  • Net income in JPY5.90bn
  • Incorporated1955
  • Employees1.74k
  • Location
    Zeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
  • Phone+81 336632351
  • Fax+81 336632352
  • Websitehttp://www.zeria.co.jp
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
GNI Group Ltd15.91bn847.96m58.27bn629.0069.482.5444,075.333.6617.6617.66333.11482.410.48051.556.6925,301,370.00-1.502.39-1.633.1785.5685.26-
Katakura Industries Co., Ltd.33.88bn1.79bn60.78bn1.06k31.970.830713.191.7953.9953.991,020.072,077.860.24942.725.3331,989,610.001.091.931.482.8436.1536.744.366.372.69--0.147521.11-5.08-4.3272.5223.98-16.809.86
Eiken Chemical Co Ltd45.03bn6.54bn69.01bn745.,208.081,329.460.70612.793.3860,436,240.0010.268.2812.8010.8548.9845.3514.5411.042.43--0.057531.2711.205.2623.2816.3420.5115.33
TORII PHARMACEUTICAL CO., LTD.48.87bn3.99bn89.28bn560.0021.820.736520.101.83142.09142.091,739.264,209.040.37822.732.4187,258,930.003.096.823.377.8549.1451.068.1715.538.03--0.0016.7812.68-4.84-3.463.51-13.220.00
TOWA PHARMACEUTICAL CO., LTD173.86bn9.36bn102.98bn4.08k10.710.70924.400.5923186.62186.623,473.482,818.590.57521.453.6842,633,890.003.105.904.337.8439.1044.125.3910.220.8056--0.51816.486.9214.2814.0123.34-8.5012.47
Shin Nippon Biomedical Laboratories Ltd21.17bn6.23bn104.00bn994.0016.693.6913.454.91149.68149.68508.61676.880.44091.605.9821,301,740.0013.055.0618.917.6553.4345.4829.6014.970.8221--0.37324.1317.460.577894.65--9.71--
KYORIN Holdings, Inc.105.53bn5.05bn107.18bn2.22k18.810.762212.121.0288.1888.181,841.562,176.730.6211.303.0447,491,000.002.973.333.664.0346.1351.064.795.461.87--0.144370.592.56-1.77-35.86-11.650.338-2.16
Zeria Pharmaceutical Co Ltd66.16bn5.90bn110.59bn1.74k15.601.4013.601.67133.42133.421,492.071,489.110.50301.533.5538,087,390.004.503.107.054.9871.9171.288.955.920.79194.670.439645.8712.84-1.7026.032.25-17.521.81
Kissei Pharmaceutical Co Ltd66.93bn12.77bn127.46bn1.83k8.880.579310.211.90276.89276.891,451.394,246.430.28481.682.5036,614,330.005.483.165.983.4248.5855.9819.2310.454.18--0.007834.12-5.31-1.83144.4810.83-5.394.01
Mochida Pharmaceutical Co Ltd109.37bn9.58bn135.74bn1.54k13.370.975511.101.24252.77252.772,899.753,464.880.6782.243.5870,835,500.005.945.227.126.4053.9951.578.757.763.62--0.0040.566.982.5123.084.3921.993.04
Data as of Feb 03 2023. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

7.90%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2022952.05k1.79%
Nomura Asset Management Co., Ltd.as of 30 Dec 2022835.50k1.57%
Asset Management One Co., Ltd.as of 15 Sep 2022677.10k1.28%
Nikko Asset Management Co., Ltd.as of 06 Jan 2023384.60k0.72%
Daiwa Asset Management Co. Ltd.as of 30 Dec 2022378.30k0.71%
Norges Bank Investment Managementas of 31 Dec 2021369.10k0.70%
BlackRock Fund Advisorsas of 05 Jan 2023220.90k0.42%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 05 Jan 2023169.10k0.32%
Charles Schwab Investment Management, Inc.as of 05 Jan 2023120.44k0.23%
Dimensional Fund Advisors LPas of 05 Jan 202391.01k0.17%
More ▼
Data from 31 Dec 2021 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.